Denemek ALTIN - Özgür
The unmissable Asia healthcare opportunity
Express Pharma
|February 2025
BCG's latest report, The Unmissable Asia Healthcare Opportunity, highlights the region's $5 trillion healthcare market potential by 2030, driven by demographic shifts, investment, and innovation.
-
This article includes key excerpts from the report, offering insights into growth drivers, investment opportunities, and the evolving healthcare landscape in Asia
The healthcare (HC) markets across Asia are highly heterogeneous, reflecting wide variations in government spending and HC infrastructure. For instance, Indonesia spends only 3.7 per cent of its GDP on HC compared to more developed markets like Singapore at 5.5 per cent. Another metric that proves this disparity is HC spending per capita, with countries like India spending only $74 per capita, falling significantly behind nations such as Thailand and Malaysia, spending $364 and $487 per capita respectively. (Refer to Exhibit 11)
Some countries lagging in WHO standards as compared to their developed counterparts have massive gaps in capacity and manpower to fill. For example, only 18 per cent of Indonesia's hypertensive patients receive drug treatment, far below the 74 per cent treatment rate in the United States. Other markets such as the Philippines (34 per cent) and Thailand (35 per cent) also face significant treatment gaps. Countries like India and Indonesia have fewer HC resources, with just 0.8 and 0.7 doctors per 1,000 people, respectively, compared to the WHO recommendation of 2.5. (Refer to Exhibit 12)
These differences underscore the need for tailored HC service models and investment strategies that consider each country's unique economic and demographic landscape. Bu hikaye Express Pharma dergisinin February 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Express Pharma'den DAHA FAZLA HİKAYE
Express Pharma
Future opportunities in biologics and biosimilars will demand significant investment
Semaglutide's patent expiry in India in March 2026 has become the immediate trigger for the next wave of pharmaceutical development activity, but the larger opportunity goes well beyond semaglutide itself.
1 mins
April 2026
Express Pharma
Gandhi Automations elevates loading bay efficiency with advanced dock leveler solutions
Engineered systems from Gandhi Automations Pvt Ltd enhance safety, durability and seamless material flow
2 mins
April 2026
Express Pharma
Redefining humidity control in pharma manufacturing
Bry-Air systems reflect shift towards material-based humidity control in pharma manufacturing
2 mins
April 2026
Express Pharma
2026 amendments to NDCT Rules: Foreword to India's biosimilars story or a step too short?
Kosturi Ghosh, Partner, and Ajeya B G, Sr Associate, in the Corporate practice at Trilegal, assess India's 2026 NDCT amendments as a timely push for biosimilars, but not enough on their own. The article highlights that stronger policy clarity and ecosystem support will be critical to truly unlock growth.
4 mins
April 2026
Express Pharma
Optima advances digital twins to boost efficiency in pharmaceutical turnkey machines
Virtual testing, training and simulation tools enhance performance in complex manufacturing environments
7 mins
April 2026
Express Pharma
Complete environmental monitoring solution – testo Saveris Pharma
There are several critical applications in the industry like research and development that demand for continuous & reliable monitoring of important environmental parameters.
3 mins
April 2026
Express Pharma
Flexotherm heating tapes & cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
April 2026
Express Pharma
Safeguarding the pharma excipients supply chain
Adding excipient details to QR codes of the top 300 drugs may not be a tough task. But as CDSCO plans to expand QR codes to cover other critical drug categories in phases, all segments of the pharma value chain need to tighten their systems, analyses Viveka Roychowdhury
15 mins
April 2026
Express Pharma
This is only the beginning of a much larger global patent-cliff cycle
As the patent expiry of semaglutide is almost there in India, several Indian pharma firms are preparing to introduce generic versions, highlighting the sector's agility in responding to high-value loss-of-exclusivity opportunities.
1 min
April 2026
Express Pharma
Leading people in the age of Al
As Al reshapes pharma, HR leadership is being drawn into a deeper question that goes beyond technology to the future of people and work, finds Lakshmipriya Nair
8 mins
April 2026
Listen
Translate
Change font size

